Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Kenyan anti-counterfeiting law to face constitutional challenge (Michael Geist) (Afro-IP)

Ecuadorian Government orders creation of public drug company (IP tango)

Mircera (Erythropoietin) – US: Amgen and Hoffman–La Roche settle Mircera litigation (Patent Docs)

Top Biotech stories of 2009 (Patents4Life)

Australia: Gene Patenting – Australian potpourri (Patent Docs)

Ecuadorian Government orders creation of public drug company (IP tango)

India and EU: Counterfeit drugs: Europe vs India? (Ills, Pills And Attendant Thrills)

India and UK: NICE, Nexavar, and why it matters (Ills, Pills And Attendant Thrills) (Spicy IP)

Israel: State of Israel sues Omrix, which commercialises medical adhesives, for half a billion, claiming that their IP is based on service inventions belonging to the State (IP Factor)

Kenyan anti-counterfeiting law to face constitutional challenge (Michael Geist) (Afro-IP)

US: Monsanto announces new policy regarding Roundup Ready Seeds (Patent Docs)

Glumetza (Metformin) – US: Depomed files patent infringement suit against Lupin following Para IV challenge(Patent Docs)

Meridia (Sibutramine) – US:Abbott Laboratories files patent infringement suit against Apotex following Para IV challenge (Patent Docs)

Mircera (Erythropoietin) – US: Amgen and Hoffman–La Roche settle Mircera litigation (Patent Docs)

Nasonex (Mometasone) – US: Schering files patent infringement suit against Apotex following Para IV challenge (Patent Docs)

Nimbex (Cisatracurium) – US: Abbott Laboratories files patent infringement complaint against Sandoz following Para IV challenge (Patent Docs)

Reminyl (Galantamine) – Spain: Court of Appeal confirms first instance decision temporarily barring Teva from marketing generic Reminyl in Spain: Janssen Pharmaceutica MV & Janssen-Cilag, SA v Teva Genéricos Española, S.L. (EPLAW)

Thrombin JM – Pharma company avoids injunction by dropping competitive keyword ads: King v ZymoGenetics (Technology & Marketing Law Blog)

Vytorin (Ezetimibe, Simvastatin) – US: Schering files patent infringement complaint against Mylan following Para IV challenge (Patent Docs)

Xeloda (Capecitabine) – US: Hoffmann-La Roche files patent infringement complaint against Roxane following Para IV challenge (Patent Docs)